Rebion

Cover Block

Name	Rebion (Rebiscan, Inc. d/b/a Rebion)
Tagline	Commercializing Neural Performance Scanning (NPS) to directly detect amblyopia and strabismus in children.
Headquarters	Boston, US
Stage	Early-revenue-stage
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware (Medical Device)
Geography	North America
Growth Profile	Venture Scale

Links

• Website: https://www.rebion.co/
• LinkedIn: https://www.linkedin.com/company/rebion

What an Investor Needs First

Rebion is a Boston-based medical device startup commercializing a hardware-first diagnostic platform that directly detects pediatric vision disorders. The company's first product, the blinq® pediatric vision scanner, is the only FDA-cleared device that directly identifies amblyopia and strabismus, delivering a pass-or-refer result in about three seconds [Rebion] [Perplexity Sonar Pro Brief]. This approach, termed Neural Performance Scanning, uses a retinal polarization scan to assess binocular function, positioning the handheld device for use by lay staff in pediatric offices and schools [Perplexity Sonar Pro Brief].

The technology's development was supported by funding from the National Eye Institute (NEI) and the National Institute of Neurological Disorders and Stroke (NINDS) [Federal Laboratory Consortium / NEI news, Aug 2025]. Rebion operates on a hardware-plus-software business model. Clinical validation underpins the commercial case: a study of 267 children reported the device detected 100% of children needing treatment for amblyopia and strabismus, with a sensitivity of 87.5% for those conditions [Newswire, Sep 2021] [Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS)].

Over the next 12-18 months, key watchpoints are the commercial rollout pace through distributors like MacGill, any disclosed private financing to scale manufacturing and sales, and the expansion of the Neural Performance Scanning platform into adjacent neurological indications such as concussion monitoring [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Core product claims and clinical data are well-cited, but company structure and financial history rely on a single aggregated source.

Taxonomy Snapshot

Axis	Classification
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	North America
Growth Profile	Venture Scale

Inside the Company

Rebion operates as an early-revenue-stage medical device company based in Boston, Massachusetts, commercializing a hardware platform it calls Neural Performance Scanning (NPS) [Perplexity Sonar Pro Brief]. The company, legally incorporated as Rebiscan, Inc. and doing business as Rebion, has focused its initial commercial efforts on pediatric vision screening, with its first product, the blinq® handheld scanner, receiving FDA clearance [Perplexity Sonar Pro Brief]. The company's public narrative centers on its technology's development, which was supported by grant funding from the National Institutes of Health, specifically the National Eye Institute (NEI) and the National Institute of Neurological Disorders and Stroke (NINDS) [Perplexity Sonar Pro Brief].

Key milestones are anchored to the development and validation of its core technology. The blinq® device was commercially launched in late 2019 [Newswire, Sep 2021]. A pivotal clinical study, published in the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS), reported the device achieved a sensitivity of 87.5% for detecting amblyopia or constant strabismus in a cohort of 267 children [Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS)]. This study was cited in a 2021 press release which claimed the scanner detected 100% of children in need of treatment for those conditions [Newswire, Sep 2021]. The company's headquarters are listed at 100 Cambridge Street in Boston [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Core company details and NIH funding are documented in multiple sources, but specific founding date and team background are not publicly available.

Under the Hood

Rebion's commercial offering centers on a single, FDA-cleared hardware device that represents a distinct technological approach to pediatric vision screening. The company's blinq® pediatric vision scanner is a handheld, portable unit that uses a proprietary method called Neural Performance Scanning (NPS) to assess how a child's eyes work together [Rebion]. Unlike traditional photoscreeners that analyze risk factors like refractive error or eye alignment, the device directly measures retinal fixation at the fovea, delivering a pass-or-refer result in approximately three seconds [Perplexity Sonar Pro Brief]. This core claim of direct detection for amblyopia and strabismus is the foundation of its marketing as the first and only FDA-cleared device of its kind [Rebion].

The underlying technology involves a retinal polarization or laser probe scan, which senses minute fixation patterns to identify the reduced bifoveal fixation characteristic of amblyopia [Perplexity Sonar Pro Brief]. This functional assessment of binocular vision is designed for use by front-line staff with minimal training, including personnel in general pediatric practices, schools, and community screening programs [Perplexity Sonar Pro Brief]. The device has been commercially available since late 2019 [Newswire, Sep 2021]. Clinical validation data supports its performance, with one study in the Journal of AAPOS reporting a sensitivity of 87.5% for detecting amblyopia or constant strabismus in a cohort of 267 children [Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS)].

Data Accuracy: GREEN -- Product claims and technical descriptions are consistently documented across the company's website, distributor listings, and NIH-funded study summaries. Clinical performance metrics are cited in a peer-reviewed journal.

Market Research

The market for early pediatric vision screening represents a persistent, high-stakes gap in preventative healthcare. The primary target conditions, amblyopia and strabismus, are among the most common pediatric vision disorders. Amblyopia, or lazy eye, is the leading cause of monocular vision loss in children, affecting an estimated 2-4% of the population [Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS)]. The American Academy of Pediatrics recommends vision screening for all children at well-child visits, creating a recurring, protocol-driven demand across tens of thousands of pediatric and family medicine practices in the United States alone.

Demand is driven by a combination of clinical guidelines and the economic burden of late diagnosis. Amblyopia is most effectively treated before age seven; delayed detection leads to permanent vision impairment, higher lifetime healthcare costs, and associated developmental delays. A significant tailwind is the shift towards value-based care in pediatrics, which rewards preventative interventions that reduce downstream specialist referrals and long-term disability. The technology's design for use by lay screeners in schools and community programs directly addresses the shortage of pediatric ophthalmologists, which creates bottlenecks for specialist-administered exams.

Key adjacent markets include concussion and traumatic brain injury (TBI) assessment, where Rebion's underlying Neural Performance Scanning platform is also being developed [Perplexity Sonar Pro Brief]. The immediate substitute market consists of established vision screening methods, including traditional photoscreeners and autorefractors. The clinical wedge for blinq® is its claim of direct functional assessment, positioning it as a more precise diagnostic aid for specific binocular disorders.

Regulatory forces are a defining characteristic of this market. blinq® holds a significant advantage as the first and only FDA-cleared device for directly detecting amblyopia and strabismus [Rebion]. Macro forces include public health initiatives aimed at reducing health disparities. Reimbursement codes from the Centers for Medicare & Medicaid Services (CMS) and private insurers for the screening procedure will be a decisive factor in commercial scaling.

Metric	Value
Pediatric Amblyopia Prevalence	3 % of population (estimated)
Recommended Screening Visits (Age 0-6)	9 visits per child
U.S. Pediatric Primary Care Practices	45000 practices (estimated)

Data Accuracy: YELLOW -- Market sizing figures are analogous estimates; clinical prevalence and regulatory claims are well-cited.

Competition and Substitutes

Rebion's competitive position is defined by its unique regulatory clearance and its direct physiological measurement, which sets it apart from a field of pediatric vision screeners that largely assess risk factors. The pediatric vision screening market is segmented by technology and regulatory status. Incumbent devices are primarily photoscreeners and autorefractors, which are FDA-cleared to detect risk factors for amblyopia like refractive error and ocular misalignment [Rebion]. These devices are widely used in pediatric practices but operate on an indirect detection model. Adjacent substitutes include traditional acuity tests like the Snellen chart, which are subjective and operator-dependent. Rebion's blinq® carves out a distinct category as the only device cleared to directly detect the neurological condition of amblyopia itself [Rebion] [Newswire, Sep 2021].

Rebion's defensible edge today rests on two pillars: its specific FDA clearance and its proprietary Neural Performance Scanning (NPS) technology. The 510(k) clearance for direct detection creates a regulatory moat that competitors cannot claim without conducting their own clinical trials and submitting new applications. The underlying technology, which scans retinal fixation via a laser probe, is patented, providing an intellectual property barrier [Perplexity Sonar Pro Brief]. However, this edge is perishable. Regulatory moats can be breached by competitors who secure similar clearances, and patent protection has a finite lifespan. The durability of Rebion's advantage will depend on its ability to iterate the technology faster than competitors can replicate it and to build a commercial footprint that becomes the standard of care.

The company is most exposed in commercial execution and market access. While it has a technological lead, it faces established incumbents with entrenched distribution channels and relationships with large pediatric networks. Companies like Welch Allyn (Hillrom) or Plusoptix have extensive sales forces and integration with broader pediatric equipment ecosystems. Rebion's reliance on a distributor like MacGill is a start, but it does not own the channel [Perplexity Sonar Pro Brief]. Furthermore, the company's focus on a single, albeit critical, application leaves it vulnerable to broader platform players that might integrate similar functionality into multi-purpose devices.

Data Accuracy: YELLOW -- Competitive positioning is inferred from the company's own claims and general market knowledge; no direct competitor profiles are cited from independent sources.

Opportunity

The prize for Rebion is a fundamental shift in how pediatric vision disorders are detected globally, moving from risk-based screening in specialized clinics to direct, point-of-care diagnosis by non-specialists.

The headline opportunity is to become the standard-of-care screening device for amblyopia and strabismus in all primary care and community settings worldwide. This outcome is reachable because the company's core technology, the blinq® scanner, has already achieved the critical regulatory and clinical validation that defines a new standard. It is the first and only FDA-cleared device that directly detects these conditions rather than just risk factors [Rebion]. A clinical study published in the Journal of the American Association for Pediatric Ophthalmology and Strabismus demonstrated the device's high sensitivity in a real-world pediatric cohort [Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS)].

Scenario	What happens	Catalyst	Why it's plausible
Public Health Mandate	State or national health authorities adopt blinq® as the required tool for school-based vision screenings.	A large-scale, government-funded validation study demonstrating cost-effectiveness and superior outcomes.	The device is already designed for use by lay screeners in community programs [Perplexity Sonar Pro Brief].
Integrated Pediatric Platform	Rebion's Neural Performance Scanning (NPS) technology expands beyond vision to become a multi-condition brain health assessment tool used at every well-child visit.	FDA clearance for a second application, such as concussion/TBI assessment, leveraging the same core NPS platform.	The company's stated technology platform is aimed at detecting and monitoring multiple brain maladies and injuries [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- The core product claims and clinical study are well-cited, but specific market size comparables and detailed expansion catalysts are inferred from the company's stated platform ambitions rather than from direct public announcements.

Sources

1. [Rebion] Rebion - The Window to the Brain | https://www.rebion.co/